Reuters logo
BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial
2017年9月11日 / 凌晨5点49分 / 2 个月前

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

Sept 10 (Reuters) - IPSEN SA:

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

* CABOZANTINIB PROVIDED STATISTICALLY SIGNIFICANT IMPROVEMENT OF PROGRESSION-FREE SURVIVAL, WITH A 52 PERCENT REDUCTION IN THE RATE OF PROGRESSION OR DEATH COMPARED TO SUNITINIB

Source text: bit.ly/2jhhRFC Further company coverage:, (Gdynia Newsroom)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below